SCHEMBL1012978

SCHEMBL1012978

O=C(COCC(=O)Nc1ccc(Cl)cc1C(=O)O)Nc1cccc(-c2cnco2)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 6/20 0.51
PORCN Q9H237 1/20 0.47
POLB P06746 1/20 0.46
G6PD P11413 1/20 0.46
IMPDH2 P12268 2/20 0.43
CCR9 P51686 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
BRAF P15056 1/20 0.42
GRIK1 P39086 1/20 0.41
PFKFB3 Q16875 1/20 0.41
PFKFB4 Q16877 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
EDNRA P25101 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015897 0.91 EDNRA (0.49) SERPINE1PORCNIMPDH2CCR9MEN1
SCHEMBL1014818 0.86 SERPINE1 (0.56) SERPINE1POLBG6PDKMT2AKDM4E
SCHEMBL1015841 0.84 SERPINE1 (0.52) SERPINE1POLBG6PDGRIK1KDM4E
SCHEMBL1015361 0.84 CNR1 (0.54) SERPINE1POLBG6PDMEN1KMT2A
SCHEMBL1014958 0.84 SERPINE1 (0.55) SERPINE1POLBG6PDMEN1KMT2A
SCHEMBL1015829 0.83 CNR1 (0.53) SERPINE1POLBG6PDMEN1KMT2A
SCHEMBL1015833 0.83 CNR1 (0.53) SERPINE1POLBG6PDMEN1KMT2A
SCHEMBL1016298 0.83 SERPINE1 (0.54) SERPINE1POLBG6PDMEN1KMT2A
SCHEMBL1016300 0.83 SERPINE1 (0.54) SERPINE1POLBG6PDMEN1KMT2A
SCHEMBL1013196 0.81 SERPINE1 (0.53) SERPINE1POLBG6PDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885PORCN 2253/4885POLB 2992/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PORCN 2981/4885POLB 2824/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PORCN 3022/4885POLB 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.